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Summary:  
 
Emerging studies increasingly demonstrate the importance of the throat and salivary glands as 
sites of virus replication and transmission in early COVID-19 disease.  SARS-CoV-2 is an enveloped 
virus, characterised by an outer lipid membrane derived from the host cell from which it buds.  
While, it is highly sensitive to agents that disrupt lipid bio-membranes, there has been no 
discussion about the potential role of oral rinsing in preventing transmission. Here, we review 
known mechanisms of viral lipid membrane disruption by widely available dental mouthwash 
components that include ethanol, chlorhexidine, cetylpyridinium chloride, hydrogen peroxide and 
povidone-iodine.  We also assess existing formulations for their potential ability to disrupt the 
SARS-CoV-2 lipid envelope, based on their concentrations of these agents, and conclude that 
several deserve clinical evaluation.  We highlight that already published research on other 
enveloped viruses, including coronaviruses, directly support the idea that oral rinsing should be 
considered as a potential way to reduce transmission of SARS-CoV-2.  Research to test this could 
include evaluating existing or specifically-tailored new formulations in well-designed viral 
inactivation assays, then in clinical trials. Population-based interventions could be undertaken with 
available mouthwashes, with active monitoring of outcome to determine efficacy. This is an 
under-researched area of major clinical need. 
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Main Text 
 
1. The viral lipid envelope 
In common with many viruses, such as influenza and herpes simplex; coronaviruses are 
surrounded by a fatty layer, called a ͞lipid envelope͟, into which the spike glycoproteins required 
for infection are inserted (Figure 1). Viral envelopes are acquired at host cell membranes—some at 
the plasma membrane, others at internal cell membranes such as the nuclear 
membrane, endoplasmic reticulum, and Golgi complex (1, 2). During this, viral proteins are 
incorporated at the expense of host cell proteins, creating the shed viral particle(3).  Thus, for 
most viruses the envelope lipids are considered to be the same as the host membranes 
(phospholipids, sphingolipids, some cholesterol). Lipid composition is not the same across 
subcellular membranes with mammalian plasma membranes having higher cholesterol and 
sphingolipid content(4-10). While the lipid makeup of the envelope of SARS-CoV-2 has not been 
characterised yet, coronaviruses are known to bud from the endoplasmic reticulum Golgi 
intermediate compartment (ERGIC), before being transported by exocytosis in cargo vesicles(11, 
12). This indicates their composition will be related to ER membrane, which contains more 
phosphatidylcholine, but less cholesterol and sphingolipids than the plasma membrane (4-10). A 
recent report demonstrated that coronavirus (HCoV-229E) regulates host lipid metabolism in 
response to infection, in common with many other viruses(13-15).  However, no information on 
the virus lipid envelope composition was provided, and its speĐifiĐ ĐoŵpositioŶ hasŶ’t ďeeŶ 
determined experimentally.   
 
2. The soap/alcohol virucidal public health advice relating to surface neutralisation. 
It is widely known that interfering with the lipid envelope represents a virucidal strategy to target 
many coronaviruses, with a large body of work evidencing the impact of many agents (16, 17).  For 
a summary, refer to Kampf et al, a systematic review providing tables showing data from different 
original publications for inactivation of coronaviruses by biocidal agents in suspension tests(17). 
During the 2003 SARS-CoV outbreak, viral material was detected on hospital surfaces, leading to 
the idea that surface decontamination would be an important approach.  At that time, various 
compounds were considered, including ethanol at high concentrations of 60-70% (v/v), since these 
doses had been found to be highly effective against several viral pathogens, including 
coronaviruses(17-19).  Recent studies on SARS-CoV-2 also support this, with high concentrations 
being highly effective as shown in a recent preprint(20).  The historical reason for only testing high 
concentrations in microbicidal research has been that these give broad spectrum activity towards 
bacteria, viruses and fungi, and thus for use on inanimate surfaces/fomites where the target 
microbes are unknown would be always preferred.  The consensus view is that enveloped viruses, 
such as herpesviruses, orthomyxoviruses, paramyxoviruses and coronaviruses are highly sensitive 
to 60-70% (v/v) ethanol with almost immediate inactivation, while non-enveloped viruses are less 
or not susceptible(17-20).   
  
We are now widely encouraged to use soap or 60-70% alcohol-based gels to inactivate SARS-CoV-
2, based on the view that these agents damage the lipid envelope, including in recent WHO and 
EPA recommendations
1,2,3
.  At the same time, there has been no discussion of oral anti-viral 
strategies, apart from a recent response to an article in British Medical Journal calling for 
protection for healthcare workers against infection
4
. Properly designed clinical trials that address 
                                                     
1
 https://apps.who.int/iris/bitstream/handle/10665/331138/WHO-WPE-GIH-2020.1-eng.pdf 
2
 https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2 
3
 https://www.who.int/gpsc/tools/GPSC-HandRub-Wash.pdf 
4
 https://www.bmj.com/content/369/bmj.m1324/rr-5  
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this issue are currently lacking in the literature. Current WHO interim guidance on clinical 
management of SARS-CoV-2 in the home is focussed on the use of personal protection, including 
face masks, along with hand, clothing and surface sanitation, to reduce risk of airborne and direct 
spread of the ǀirus, ďut doesŶ’t ŵeŶtioŶ oral hǇgieŶe5.  Thus, its utility in the setting of SARS-CoV-
2 has not been considered systematically, and there is a lack of either positive or negative robust 
clinical evidence.  
 
Mouthwashes vary widely in composition; however, some commercially available formulations 
contain ethanol at 14-27% (w/v) in the UK, Europe and US.  Prompted by this, we reviewed the 
available scientific literature to establish whether oral treatment using ethanol-based or other 
types of mouthwashes could present a strategy to either dampen or reduce viral load, to 
potentially restrict virus transmission in the current pandemic situation, particularly for vulnerable 
individuals or healthcare workers.  We found that there is a paucity of data systematically testing 
the impact of lower (less toxic) ethanol concentrations on enveloped virus inactivation, with most 
simply reiterating the use of the higher concentrations described above(16, 18, 19, 21-24).  We 
also found a paucity of robust clinical studies in this area that address in a randomised double-
blind manner the impact of oral rinsing on objective measures, specifically neutralisation of 
enveloped viruses, including coronaviruses.   
 
3. Viral load, saliva/throat virus and disease severity in SARS-CoV-2. 
It is becoming increasingly recognised that the throat is a major site of replication and shedding of 
virus in COVID-19 illness, and that viral load is important(25).  Throat and sputum are abundant in 
particles, which peak 5-6 days after symptom onset, and decline thereafter(26, 27). Viral load 
correlates with older age(27), and a study of 76 patients in Nanchang, China, showed that those 
with severe SARS-CoV-2 tend to have higher viral load and longer virus-shedding period than those 
with mild disease(28).  Similarly, viral load was linked with lung disease severity in a study of 12 
patients with pneumonia(29).  Many asymptomatic individuals have modest levels of detectable 
viral RNA in their oropharynx for at least 5 days, which is similar to individuals with clinical 
symptoms(30). Data from GTEX gene expression data indicates that ACE2 (a key receptor for 
COVID-19) expression is higher in salivary glands than lungs, suggesting that the these could be a 
major source of new viral particles(31).   A recent study using mobility data and Bayesian inference 
inferred that a high rate of undocumented infections is responsible for rapid spread of SARS-CoV-
2(32). Taken together, these data suggest that the potential for transmission is high early in the 
disease. While further studies are needed to better understand the relationship between viral load 
and symptom severity, it is expected that higher levels of viral shedding in the throat or lungs 
might be associated with an increased ability to infect others. To date, the relationship between 
lung and throat viral load in terms of disease severity, is not clear, and how dampening throat 
virus load may impact on resulting lung disease or viral transmission is not known.   
 
The route of SARS-CoV-2 infection is currently considered to be via respiratory droplets, similar to 
SARS-CoV (33), and the virus particle is viable in aerosols for up to 3 hrs (34). Although ǁe doŶ’t 
yet know the minimal infectious dose, the high rate of transmission indicates this is likely to be 
relatively low.  If correct, then strategies to reduce the number of infective virus particles in 
mucous membranes through promoting their removal or inactivation could contribute to reducing 
risk of transmission.  Thus, assuming that the throat is a major site of replication in early stages 
(even before symptoms are apparent), then oral washing using agents that could damage or 
destroy the lipid envelope have the potential to reduce viral load in the oropharynx.   
 
                                                     
5
 https://apps.who.int/iris/handle/10665/331133  
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At this time, there is incomplete information on how SARS-CoV-2 moves from the throat and nose 
to the lungs, and this could include (i) viral shedding, (ii) the aspiration of necrotic cell debris, or 
(iii) direct infection of neighbouring cells.  Assuming viral shedding is involved, then oral rinses that 
target the viral lipid envelope represent a potential method to remove/rinse or inactivate infective 
particles generated in the throat.  The specific intracellular replication cycle for SARS-CoV-2 in 
humans is not yet known. Based on non-synchronised replication cycles that take  < 24hrs, virus is 
likely to be secreted almost constantly (35, 36)  Oral agents will impact only on virus that is 
extracellular or actively budding. Therefore, the persistence of treatment will be important.  How 
long mouthwash components retain an ability to interact with biomembranes in the mouth is 
unclear, and more research is required.   
 
4. The impact of lower ethanol concentration on biomembranes. 
When considering lower (non-toxic, more economical) ethanol concentrations, the literature on 
mammalian cells (from where the lipid envelope originates) provides a close comparator. We also 
reviewed studies on model membrane vesicles comprising phospholipids such as 
phosphatidylcholine; however, as these are protein-free, the impact of non-lipid components on 
ethanol toxicity is not accounted for.  Bacterial pathogens contain very different membranes in 
lipid and protein composition, including lipopolysaccharides and peptidoglycans, so are not 
considered here.  Below we summarise the literature on impact of ethanol on cell/model 
membranes (Table 1). 
 
(i) Low concentrations of ethanol cause swelling, interdigitation, and leakage in model 
membranes. Biophysical studies in the 1980s and 90s compared various alcohols (ethanol, 
methanol, butanol, propanol) for their ability to perturb model phospholipid membranes. Many 
were optimising generation of lipid vesicles for drug delivery; however, the toxicity of most 
short chain alcohols prohibits oral use. Here, we reviewed reports on the properties of ethanol 
on model membranes.  Few studies directly investigated lysis, instead focusing on membrane 
fluidity, permeability, interdigitation, thickness, and other parameters.  In one study, ethanol > 
3.4 M (20% v/vͿ resulted iŶ ŵeŵďraŶes Ŷot ďeiŶg ĐoŶsidered ͞staďle͟(37).  Ethanol addition 
causes rapid swelling of phosphatidylcholine vesicles from around 30 nm diameter at 0 M, up to 
between 80 - 110 nm diameter, at 1.1 - 1.5 M (6.5 - 8.8% v/v)(38).  Interdigitation refers to the 
process whereby the presence of short chain alcohols enables the methyl group of the fatty 
acyl chains to move beyond the midplane of the bilayer, penetrating the opposite monolayer, 
and appears to be an event that precedes and promotes vesicle fusion and leakage (39, 40). 
Several studies demonstrate that ethanol promotes interdigitation(41). In one, ethanol at 
above 2 M (11.8% v/v) led to formation of interdigitated phospholipid sheets from small 
unilamellar vesicles (SUV), that then annealed to form larger interdigitation-fusion vesicles 
(IFVs)(42). This means that ethanol at this concentration can deform small phospholipid vesicles 
leading to fusion and formation of larger structures. During this process, leakage of contents 
from vesicles is seen (38, 42-44).  Three studies compared membranes consisting of either 
phosphatidylcholine alone, phosphatidylcholine/phosphatidylethanolamine mixtures, or 
phosphatidylcholine /cholesterol mixtures, and showed that all became permeable at ethanol 
concentrations around 0.6-2.1 M (3.5-12.3 %, v/v)(38, 45, 46). Elsewhere, ethanol at rather 
lower concentrations of 86mM (0.5% v/v) caused lysis of phosphatidylcholine vesicles during 
repeated cycling through phase transition temperatures(47). Partitioning of ethanol into the 
membrane can be altered through the presence of additional biologically relevant lipid species 
such as cholesterol or gangliosides(45, 48, 49). This indicates that complex biological 
membranes may respond very differently, and not only the presence of other lipid types, but 
also the impact of proteins need to be taken into account.  Nonetheless, it is clear that model 
membranes are sensitive to ethanol at concentrations far lower than the 60-70% currently 
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recommended for inactivation of virus on hard surfaces, and at amounts contained in widely 
available mouthwashes (See Section 6).    
(ii) Impact of ethanol on mammalian cell membranes.  
We also reviewed the impact of ethanol on mammalian cells in vitro. Of direct relevance to 
coronaviruses, a study on corneal epithelial cells showed that a 30 sec incubation with 20% 
ethanol led to around 40% loss of viability, which increased to 70% loss at 40% ethanol.  There 
was significant leakage of intracellular contents following 20% ethanol for 30 sec(50).  This 
short incubation also altered inflammatory responses, differentiation and epithelial marker 
expression(50).  Several studies on the impact of ethanol on red blood cells were also found.  
Sonmez et al showed that around 1M (5.9% v/v) causes ˜10% cell lysis, but higher amounts 
were not tested (51). A variety of effects on red cells have been shown including potassium 
leakage and haemolysis, at moderate concentrations around 3 - 4M (18–23.5% v/v). However, 
incubation times of 15 min or greater were generally used(52-54).  Last, a study on an intestinal 
cell line (Caco-2) showed that ethanol > 5-10% causes loss of viability, leakage of contents and 
disruption of tight junctions, with a long incubation time of 60 min (55).  Since the membrane 
composition of coronaviruses is expected to match ERGIC (see Section 1), these studies provide 
strong evidence that low ethanol will directly impact on the SARS-CoV-2 membrane also.  
 
So far, we found only studies that tested the impact of reduced ethanol amounts on enveloped 
viruses. Both were conducted in vitro, and show positive outcomes in relation to virus 
denaturation.     In  2007, Roberts and Lloyd found that 20% ethanol completely inactivated three enveloped 
viruses: Sindbis, herpes simplex -1 and vaccinia, in vitro, while having no effect on the non-
enveloped poliovirus-1(56).  Inactivation was measured by inhibition of plaque forming units 
in a viral infectivity assay, but direct impact on viral envelope was not determined.  This study 
used a rather basic system, in the absence of a soil load, which is nowadays recommended 
under the ASTM Committee E35 on Pesticides, Antimicrobials and Alternative Control Agents
6
, 
or in the UK, the equivalent BS EN standard
7
 Also, it was conducted at 22 °C, rather than the 
more relevant 36.8 °C oral temperature, where the impact of denaturation agents would be 
greater.    In 2017, Siddharta and colleagues tested WHO recommended formulations against enveloped 
viruses, including coronavirus.  Focusing on WHO formulation I, which contains 85% (v/v) 
ethanol, 0.725% (v/v) glycerol and 0.125% (v/v) hydrogen peroxide, they measured in vitro 
infectivity in the presence of a soil load (0.5% w/v bovine serum albumin).  A 30 sec exposure 
of a dilution containing 34% (v/v) ethanol (40% of neat) completely prevented subsequent 
viral replication(57).  
 
These studies indicate that relatively dilute ethanol will be highly effective against enveloped 
viruses. However, there is an urgent need to determine how coronaviruses are impacted by dilute 
alcohol under biologically-relevant conditions (mucosa, mouth, etc), and whether in combination 
with non-toxic, membrane disrupting agents, oral inactivation of SARS-CoV-2 could be achieved.  A 
minimum amount of ethanol, e.g., 10-30% (v/v) would be effective, and contact time will also be 
an important parameter that may reduce ethanol exposure required.  Ethanol impacts membrane 
properties of artificial lipid membranes, causing leakage of contents even in the absence of 
                                                     
6
 https://www.astm.org/Standards/E2197.htm  
7
 BS EN 14476:2013+A2:2019 
Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the 
medical area. Test method and requirements (Phase 2/Step 1), 
https://shop.bsigroup.com/ProductDetail?pid=000000000030401479  
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complete lysis. The ability of the virus to infect host cells could also be modified by inducing 
biophysical changes to the virus membrane which impact on protein function. The spike 
glycoprotein which is required for SARS-CoV-2 infectivity contains a transmembrane domain which 
is inserted into the viral envelope(58), and it is well known that lipid membrane biophysical 
perturbations can impact on  conformation and function of many transmembrane proteins in 
mammalian cells. In this regard, the lipid membrane of HIV-1 was recently demonstrated to 
stabilise viral membrane glycoproteins, and regulate their sensitivity to neutralisation by 
antibodies(59). Thus, lower concentrations of ethanol could alter pathogenicity without complete 
neutralisation of viral particles.  Research is required to determine the impact of ethanol or other 
agents on the infective activity of the SARS-CoV-2 spike protein in vivo.   
 
5. Membrane perturbation without lysis can dampen enveloped virus infectivity  
The concept that perturbing the membrane could inactivate viruses has recently been tested in 
relation to membrane-disrupting agents, and an in vitro screen of 1000 compounds identified a 
series of lipidomimetics that can alter the membrane and dampen infectivity of HIV-1(60).  Active 
agents included lipids related to cholesterol, sphingosine or aliphatic lipids with long chain fatty 
acids which blocked at the stage of entry into the host cell.  The impact appeared to result from 
the lipids being incorporated into the membrane and inducing changes in lipid order and buoyant 
density of the particles.  In support of this, a studǇ iŶ the ϭ97Ϭ’s shoǁed that fatty acids and 
monoglycerides of 16-18 carbon chain length are highly effective in vitro, reducing survival of 
herpes simplex virus to around 50% at concentrations down to 0.2M (61).  These studies use 
compounds that are non-toxic to mammalian cells and show great promise, thus research is 
needed to determine whether they are also active against the envelope of SARS-CoV-2 both in 
vitro and in vivo. 
 
6. Mouthwash preparations that show activity against enveloped viruses in published studies. 
We investigated the potential for commercially available mouthwashes to disrupt viral lipid 
envelopes, either due to ethanol (Table 1), or other active agents, through reviewing available 
literature.   
 
Three industry-sponsored studies from the Universities of Maryland, Texas-Houston Health 
Sciences Centre and State University New York tested this using a widely available formulation 
that combines 21-26% ethanol with essential oils  (eucalyptol 0.092%, menthol 0.042%, methyl 
salicylate 0.060%, and thymol 0.064% w/v).  Notably, there is published evidence that eucalyptus 
oil and thymol have significant antiviral properties towards herpes simplex virus at these 
concentrations, hypothesised to relate to disruption of the viral lipid envelope(62).   
  The virucidal actions of 21% (v/v) ethanol with essential oils towards an enveloped virus were 
reported in humans in vivo in 2005.  A 30 sec rinse reduced infectious virions of herpes simplex 
types I and II to effectively zero(63).  Specifically, 18/20 people demonstrated no virions post-
rinse, and after a 30-min rinse, virions remained at zero for 11/20 subjects, with all subjects 
remaining lower than pre-rinse levels.  In contrast, rinsing with distilled water reduced mean 
virions considerably less post 30-sec rinse, and levels had largely returned to baseline by 30 
min.  This indicates that the mouthwash had a specific and significant impact on virion 
recovery.   In a repeat trial, 18/20 subjects had zero virions post 30-sec rinse, with 12/20 
remaining at zero at 30 min.  At 60 min, all 20 were still shedding virions at 1-2 log10 lower than 
baseline, demonstrating a modest impact on viral titre. Longer contact times (e.g., 60 sec 
rinses) were not tested(63).  Herpesviruses differ from coronaviruses in that the former can 
erupt periodically from where they reside in the nerves; so, using a mouthwash may 
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temporarily reduce the level and it may then help promote resolution of the lesion.  On the 
other hand, coronaviruses will be shed almost constantly when actively replicating.  A study in 1995 tested 26.9% ethanol with essential oils against herpes, influenza, rotavirus and 
adenovirus in vitro.  Here, an impact on the viral lipid envelope was speculated since herpes 
and influenza were significantly impacted, while adenovirus and rotavirus (non-enveloped) 
were not(64).    A follow up unpublished study in 2010 determined that a 30-sec in vitro exposure to  21.6% 
ethanol with essential oils led to >99.99% reduction of infectivity of H1N1 Influenza A pandemic 
strain
8
   
 
These studies provide proof-of-concept that mouthwashes containing essential oils with 21-27% 
ethanol can inactivate enveloped viruses, both in the lab and in humans, with the likely 
mechanism being damage to the lipid envelope. Here, ethanol in combination with essential oils 
may provide a more effective formulation. Thus, these types of mouthwash may be effective 
against SARS-CoV-2, although studies have not been conducted. Whilst other commercially 
available ethanol mouthwashes generally contain lower levels without essential oils, an impact on 
membrane biology may remain theoretically possible, and studies are required.   
 
(ii) Chlorhexidine.   
Chlorhexidine is widely used for oral health in the UK, being especially effective against Gram-
positive bacteria, but to a lesser extent Gram-negative bacteria and fungi(65).  Due to its positive 
charge, it reacts with the negatively charged microbial surface, penetrating into the cell and 
causing leakage.  A report on its in vitro viricidal effectiveness at 0.12% has indicated it can reduce 
the viral concentration of enveloped but not non-enveloped viruses(66).  However, this limited  in 
vitro study only considered the immediate post-exposure, and no further time points were 
included in the experimental design. Chlorhexidine is often formulated with ethanol at lower 
concentrations, which may in part explain its virucidal impact.  A recent review of coronavirus 
literature identified that chlorohexidine exposure for 10 min only weakly inactivated coronavirus 
strains in suspension tests although the concentration used was low at 0.02% (17, 22). 
Chlorhexidine formulations have been shown to retain oral antimicrobial activity for up to 12 
hrs(67). It is a more effective antimicrobial in vivo because it binds to clean oral surfaces and is 
released over time (substantivity)(67). Despite lower activity towards coronaviruses, a 
combination of chlorhexidine with alcohol may offer a useful strategy for reducing viral load over 
longer times. 
 
Chlorhexidine mouthwashes have been a critical clinical tool for over 40 years to reduce oral 
bacterial flora and prevent infection and mucositis in cancer patients receiving chemotherapy and 
radiotherapy(68-70).   However, there are no reported studies assessing the impact of 
mouthwashes in specifically preventing or treating viral infections in neutropenic patients.  Last, a 
recent meta-analysis showed that chlorhexidine (rinse or gel) can reduce risk of ventilator-
associated pneumonia in patients undergoing mechanical ventilation, although causative 
organisms were not described(71)  
 
(iii) Povidone-iodine.   
Povidone-iodine (PVP-I) mouthwash has been widely studied in relation to broad spectrum anti-
microbial and virucidal actions.  At 0.23%, which is routinely used in Japan, this rapidly inactivates 
SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus in vitro (72).   A second study also 
                                                     
8
 https://iadr.abstractarchives.com/abstract/2010dc-131191/evaluation-of-h1n1-antiviral-properties-of-an-essential-oil-containing-
mouthrinse   
 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/fu
n
c
tio
n
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/fu
n
c
tio
n
/z
q
a
a
0
0
2
/5
8
3
6
3
0
1
 b
y
 g
u
e
s
t o
n
 1
6
 M
a
y
 2
0
2
0
 8 
showed that PVP-I (0.23%) is equivalent to 70% ethanol in inactivating SARS-CoV in vitro(73).  
Indeed, based on in vitro and limited clinical studies, in Japan, the Ministry of Health, Labour and 
Welfare supported daily gargling as a protective measure to prevent upper respiratory tract 
infections(74).  A small number of human studies supporting this in the case of PVP-I have shown 
reduced incidence of both bacterial and viral (influenza) infection through repeated gargling(75) 
(72).  In one rather limited study, the absence rate in middle schools in Yamagata City were 
compared over 3 months, where PVP-I gargling was encouraged in 1 school, versus 7 where it was 
not. A reduction of absence due to colds and influenza from mean of 25.5% (no gargling) down to 
19.8% (p<0.05) was found(76).  In another study, a group of 23 patients gargled more than 4 
times/day for up to 2 hrs.  Here, acute exacerbation of chronic respiratory infection was reduced 
by around 50% (75).  This mouthwash is not available in the UK, although may still be purchased in 
Germany and other countries.  As a 1 % solution, PVP-I is available in Hong Kong, Korea, Singapore, 
Malaysia, Philippines and Taiwan.  The importance of higher concentrations of PVP-I as a broad-
spectrum antimicrobial agent for topical uses is indicated by its inclusion on the World Health 
OrgaŶizatioŶ’s List of EsseŶtial MediĐiŶes9. It should be noted that rare allergic reactions have 
been reported for PVP-I(77) 
 
(iv) Chlorinated water or hypertonic saline rinsing 
Studies from Japan surprisingly found that gargling with chlorinated tap water reduced respiratory 
infections, and in one, was even better than PVP-I. In one, three groups of around 130 age- and 
gender-matched human subjects were studied (three 15 second gargles with 20ml, at least 3/day 
for 60 days)(78).  Tap water reduced incidence of common cold by 36%, while PVP-I was not 
effective.  It was speculated that chlorine in the water may have contributed, since levels in Japan 
were above concentrations that are known to have viricidal activity including towards enveloped 
species(79).  However, information on the virucidal impact of chlorine comes from in vitro studies, 
including one with a 30 min contact time, and its impact in vivo on enveloped viruses, through 
gargling tap water is not known(79).  In 2008, another trial calculated economics of the activity in 
two groups of around 120 subjects gargling water for 60 days, and concluded that this was a cost-
effective strategy for upper respiratory infection prevention(80).  Last, a recent study showed that 
gargling and nasal rinsing with hypertonic saline could reduce symptoms, duration of illness and 
viral shedding.  However, this was a pilot, non-blinded, self-reported study and so cannot be 
considered definitive(81). A follow up study in vitro with enveloped and non/enveloped viruses 
including human coronavirus 229E suggested that this may have been related to altered 
intracellular chloride levels and peroxidase activities(82). None of the in vivo studies addressed the 
issue of ǁhiĐh pathogeŶs ǁere ĐoŶtriďutiŶg to illŶess, aŶd so ĐaŶ’t ďe eǆtrapolated to 
coronaviruses.  
 
Separate to oral rinsing it is worth noting that nasal rinsing with saline is a popular method 
promoted to clear nasal passages for sufferers of colds and allergies.  Given that virus is recovered 
in the nasopharynx, a similar consideration of how this might be used as preventative measure 
could be made.  As for mouthwash, clinical studies have not systematically examined how 
effective nasal rinsing is for preventing respiratory infections.  Notably, rare reports of serious 
illness when not properly cleaned, due to the presence of parasitic amoebae in unboiled tapwater, 
has led to recommendations on careful disinfection of rinsing syringes being made by CDC
10
.   
 
(v) Hydrogen peroxide.  
                                                     
9
 https://www.who.int/medicines/publications/essentialmedicines/en/   
10
 https://www.cdc.gov/parasites/naegleria/sinus-rinsing.html 
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Hydrogen peroxide causes oxygen free radical-induced disruption of lipid membranes and is 
widely used as an agent for tooth whitening. Studies, including a recent systematic review, report 
that coronavirus 229E and other enveloped viruses are inactivated at concentrations around 0.5% 
(17, 83). Whilst higher concentrations of hydrogen peroxide (>5%) will induce damage to both soft 
and hard tissues, within the range of concentrations used in mouthwashes for whitening at 1-3% 
little damage is reported (84). Within the oral environment hydrogen peroxide is rapidly 
inactivated due to the presence of host- and bacteria-derived catalase activity in saliva and other 
endogenous peroxidases(85). The impact of peroxidases could theoretically be reduced by using a 
pre-rinse with water, although this is untested.  A consideration with this agent is that it can have 
potential pro-viral activities, although so far this was only seen in vitro (86-88). 
 
(vi) Quaternary ammonium compounds 
These are widely used as microbicidal agents that interfere with protein or lipid components on 
the cell surface, particular of Gram-positive or Gram-negative bacteria.  Their virucidal activities 
are not widely reported although some reports against enveloped viruses have been made in the 
literature relating to surface disinfection(79).   Among this group of compounds, cetylpyridinium 
chloride (CPC) was recently shown to have activity against influenza both in vitro and in vivo, 
through direct attack on the viral envelope, with in vitro EC50 being 5-20 g/ml (89).    CPC is used 
in medicated oral rinses at concentrations 0.025-0.075% w/v (250-750 µg/ml) in the UK, while 
lozenges sold in some countries contain 1.4-3.0 mg of CPC.  
 
7. Current policies relating to oral health and use of microbicides in dental practice and with 
immunosuppressed individuals. 
Dental practitioners are at elevated risk of exposure to SARS-CoV-2, and there are guidelines that 
advocate use of mouthwash clinically.  Previously published CDC guidelines for infection control in 
the dental setting have cited the potential usefulness of pre-procedural mouthwashes in reducing 
the spread of airborne pathogens of all type(90). Indeed, studies have addressed how virucidal 
components including cetylpyridinium chloride and chlorhexidine can be effective in reducing 
bacterial contamination in this setting, although virus inactivation was not tested (91, 92)   Meng 
et al. in an experience-based review of their practice in Wuhan, recommended pre-procedural 
mouthwash to reduce the oral microbial load in patients undergoing dental treatment in patients 
with SARS-CoV-2(93).   Last, two  recent papers aimed at providing guidelines for endodontists in 
relation to SARS-CoV-2 advocated pre-procedural mouth rinse with 0.2% PVP-I (94, 95). Given that 
the dental community recognise the potential for oral mouthwashing in relation to reducing 
infection risk, extrapolating these guidelines to the wider community is worth a full discussion.  
 
8. The urgent need for research  
Many questions need to be addressed in relation to whether oral hygiene could represent a viable 
approach to dampen transmission of SARS-CoV-2, and research is required to address this.   
 
In relation to oral hygiene, we need to determine:  Can we reduce viral load in the oropharynx through oral rinsing?  If we can reduce load, then which oral rinse would be clinically effective: The current choice 
includes 20-30 % ethanol, lipid-based membrane disruptors, PVP-1, CPC, hydrogen peroxide, 
simple chlorinated tap water or WHO formulation I diluted to 30% of neat?   Would a combination of agents in lower amounts be better tolerated, reducing adverse effects, 
and remain effective?  What combinations or agents, contact time and frequency of use would induce anti-viral 
activity and reduce infectivity of SARS-CoV-2 
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Available research approaches include: 
 
(i) Statistical epidemiological studies could establish on a population level whether mouth rinsing 
is associated with reduced rates of throat and respiratory infections including SARS-CoV-2.  
Purchasing data of health-related products to model health linkages
 
could be used. New 
applications to conduct widespread monitoring of SARS-CoV-2 symptoms, could capture use of 
mouthwashes to test for correlation with symptoms and severity, alongside wider purchasing sales 
behaviour of those who are asymptomatic. Modelling approaches should also consider population 
usage of mouthwash preparations and viral spread. 
 
(ii) Underpinning research. Not all enveloped viruses are the same, and herpes, influenza and 
measles viruses are considered more unstable than human coronaviruses, which may persist for 
up to 5 days on inanimate surfaces(17, 34, 96). Thus, research needs to focus on coronaviruses in 
particular.  The exact composition of the SARS-CoV-2 lipidome needs to be determined using 
lipidomics mass spectrometry.  Research should determine the impact of ethanol or other agents 
on the infective activity of the spike protein itself, in vitro and in vivo.   A useful virus to test in 
vitro would be the human respiratory coronavirus 229E which is used extensively as a surrogate 
for human coronaviruses but only requires Cat2 procedures, and its replication and propagation 
conditions are well established already. This would be a good representative for pathogenic 
coronaviruses, prior to narrowing down to SARS-CoV-2 which requires Cat3 biosecurity.  
 
The impact of temperature and soil load needs to be considered for in vitro studies, applying the 
ASTM or EU standard protocols
11
.  Here, the impact of not only dose/composition but also the 
critical issue of contact time with agents, which is a known modifiable parameter of virucidal 
activity can be easily tested. The virucidal mechanisms can be determined, conducting lipidomics 
analysis of the envelope along with assays that determine spike protein conformation and activity. 
While a particular ethanol concentration may achieve full inactivation, lower amounts could either 
help to remove virus, or lead to membrane damage (permeability/leakage) that may impact throat 
cell virus infectivity, e.g. through potential modification of the ability of the spike glycoprotein to 
interact with receptors on host cells.  In this regard, for HIV-1, the lipid membrane stabilises 
membrane glycoproteins, regulating their sensitivity to antibody neutralisation (59). This type of 
action could be further enhanced if membrane disrupting agents were also included in a 
mouthwash.  Indeed, lipidomimetic compounds have already been developed that can dampen 
viral infection through affecting lipid membrane structure or curvature (discussed in Section 5).   
 
Most virucidal research uses in vitro models, where the response to the agent will be different, 
and also does not take into account the impact of host immunity.  There is an absence of animal 
model studies on coronavirus respiratory illness, although macaques and mice transgenic for 
humanised ACE2 are beginning to be studied with early indications being that both develop mild 
illnesses in response to SARS-CoV-2 virus
12
.   
 
(iii) Clinical studies. Robustly designed, appropriately-powered in vivo clinical studies are needed, 
including determination of the most effective composition. Self-reported, non-randomised, 
unblinded studies are not reliable and need to be avoided.  An important sequela of these over the 
counter medicines is that individuals may use them prior to providing diagnostic 
nasopharyngeal/throat swabs. This could increase the number of false negative tests and facilitate 
transmission. Currently there is no specific advice to avoid these preparations prior to testing. 
                                                     
11
 https://www.astm.org/Standards/E2197.htm 
12
 https://www.nature.com/articles/d41586-020-00698-x  
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(iv) Population based interventions could be considered, although panic buying or dangerous 
consumption of ethanol or methanol has to be avoided.  As high-risk groups come out of self-
isolation, they could represent a population to evaluate clinical outcomes resulting from real-
world use of available mouthwashes. The current social restrictions will reduce a number of 
transmission risk factor variables and alter clinical outcomes in terms of SARS-CoV-2 infection, 
other respiratory infections, and adverse effects, but monitoring outcomes could provide useful 
data.  Users could be given general advice on product use, recording timings and duration of 
gargling for later analysis, or act as controls.  Similarly, health workers at high risk of infection 
could be provided products and asked to record their use and report outcomes. Ideally, throat 
swabs and blood samples would be obtained for testing.  There would be logistical, ethical and 
regulatory issues involved in setting up investigations. However, given the theoretical plausibility 
and data we have reviewed plus the readily available products and urgent need to reduce SARS-
CoV-2 infection, measures could be considered and action taken to instigate clinical investigation 
in the population during the outbreak.  
   
(v) Host inflammation. Mouthwashes widely utilised in daily oral and dental hygiene for cosmetic 
and medical reasons and have demonstrated acceptable tolerability when used multiple times 
daily for durations of 6 months and longer. Despite this, the impact of rinsing with these agents on 
throat tissue health needs to be seriously considered, since the viral lipid membrane is effectively 
the same as that of the host.  Some of these agents, such as ethanol and hydrogen peroxide may, 
if used several times a day over a period of 2-3 months, induce mucosal inflammation.  This was 
observed in a study on corneal epithelial cells, where inflammatory cytokines (IL-1b, IL-6), 
chemokines (IL-8/CXCL8), CCL2) and matrix metalloproteases (MMP9) were all upregulated at the 
mRNA level 1-3 days after a 30 second exposure to 20% (v/v) ethanol(50). Here, it will be 
important to ascertain whether a repeated daily rinse with mouthwash would have any 
detrimental impact on the stromal tissue lining.  Alternatively, host innate immune responses in 
early infection could also represent a strategy to remove virus, and this has not been considered in 
any studies to date.  Significant advances have been made into the molecular basis of alcohol-
induced tissue injury. However, these studies tend to be confined to studies of acute and chronic 
alcohol consumption where the metabolism of alcohol into acetaldehyde and reactive oxygen 
intermediates modify various physiological processes linked with the maintenance of tissue 
homeostasis(97). Currently, there is a lack of research into the potential impact of mouthwash on 
local inflammation within the throat and consideration needs be given to both its impact on anti-
viral immunity and the disruption of tissue integrity.    
 
Additional Reading:  We highlight a list of excellent review articles that were consulted as part of 
preparing this review and were a source of primary research cited herein: 
Budding of viral lipid membranes: Simons et al (98) 
Impact of virus on lipid metabolism: Sanchez and Lagunoff (99) 
Review of inactivation of coronaviruses on surfaces: Wolff et al (100) 
Emergence of SARS-CoV in 2003: Peiris et al (101) 
Two papers on the impact of ethanol on interdigitation of membranes: Slatter et al (102, 103) 
Control of infection using Povidone-Iodine: Eggers (104) 
Summary of the composition of lipid membranes in cells: Van Meer (105) 
 
Search strategy 
Since the review covers many areas from basic biochemistry, virology and microbicidal research, 
as well as clinical information both in medicine and dentistry, multiple sources were consulted.  
Most references were identified from PubMed, Researchgate or Google, using search terms 
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iŶĐludiŶg ͞ǀirus͟, ͞ĐoroŶaǀirus͟, ͞lipid eŶǀelope͟, ͞alĐohol͟, ͞ŵeŵďraŶe͟, ͞ĐhlorheǆidiŶe͟, aŶd 
others, alone and in combination. Many references that were first identified, were then 
investigated further to find additional source material and the original primary research which was 
then included.   The idea for draftiŶg the reǀieǁ ǁas iŶitiated ďǇ O’DoŶŶell oŶ Ϯϭ/Ϭϯ/ϮϬϮϬ, 
through reaching out in person to various international experts, to get their views and input 
directly, via phone calls and then follow up emails.  Boots UK were approached initially to discuss 
the ideas, and for information on formulation of available mouthwashes.  Boots researchers and 
scientists contacted Johnson&Johnson, who provided proprietary information.  Boots researchers 
;Kirkdale, ThorŶleǇ, PoǀeǇ, IŶĐhleǇ, O’“heaͿ theŶ ĐoŶduĐted further searĐhes of PuďMed, Google 
and Researchgate, using the same terms.  Academic and clinical expertise was consulted for 
virology (Stanton, Humphreys, Bosch), clinical/ICU (Fegan, Wise), dental practice (Thomas), 
iŵŵuŶologǇ ;JoŶesͿ, lipid ďioĐheŵistrǇ ;Wakeleŵ, MurphǇ, “iŵoŶs, O’DoŶŶellͿ aŶd ŵiĐroďiĐides 
(Sattar, Maillard).  Phone/email correspondence with experts generated input, opinions and 
identified additional references.  No timeline for references was used and no languages were 
excluded.   
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 Reference Study Type Ethanol Results 
Ly HV et al (2004) 
(37) 
Model membrane vesicles (membrane fluidity, 
permeability, interdigitation, thickness, etc)  
Ethanol > 3.4 M (20% v:v)  MeŵďraŶes Ŷot ĐoŶsidered ͞staďle͟ ; 
Interdigitation; rapid swelling of PC vesicles  
Ahl PL et al (1994) 
(42) 
Formation of interdigitated PL sheets from 
small unilamellar vesicles (SUV), 
Ethanol above 2 M (11.8% v:v) Formed larger interdigitation-fusion vesicles 
(IFVs); leakage of contents of vesicles 
Hunt GR et al (1983) (47) Repeated cycling through transition phase of 
model membranes 
Ethanol 86mM (0.5% v:v) Lysis of PC vesicles  
Komatsu et al (1995, 1995, 
1997 (43,45,46) 
Leakage of dye from vesicles made of PC, 
PE/PC or PC/cholesterol. 
0.6-2.1 M (3.5-12.3 %, v/v) Calcein leaks out at low ethanol 
concentrations. Rapid swelling of vesicles.  
Dennison DK et al (1995) 
(64) 
In vitro - Herpes, influenza, rotavirus and 
adenovirus 
26.9% ethanol (v:v) with 
essential oils 
Enveloped viruses (herpes and influenza) 
were significantly impacted 
IADR abstract 2010 
(footnote 8) 
H1N1 Influenza A pandemic strain, in vitro 21.6% ethanol, 30 second rinse >99.99% reduction in infectivity  
Roberts and Lloyd (2007) 
(60) 
Three enveloped viruses: Sindbis, herpes 
simplex -1 and vaccinia, in vitro 
20% (v:v) ethanol Completely inactivated  
Siddharta A et al (2017) 
(61) 
Enveloped viruses; in vitro infectivity WHO 
formulation I in the presence of coronavirus.   
30 sec exposure of a dilution 
containing 34% (v:v) ethanol  
Completely prevented subsequent viral 
replication 
Oh JY et al (2013) 
(50) 
Mammalian cell membranes:  
Corneal epithelial cells 
20% ethanol; 30 sec incubation  40% loss of viability; High level of leakage of 
intracellular contents  
Sonmez M et al (2013) (51)  Mammalian cell membranes: Red blood cells  1M (5.9% v:v) ethanol ˜10% cell lysis  
Chi LM (1991) 
Tyulina OV (2000), (2002)     
(52-54) 
Mammalian cell membranes:  
Red blood cells 
Moderate concentrations 
around 3 - 4M (18 – 23.5 %). 
Potassium leakage and haemolysis 
Wang Y et al (2014) 
(55) 
Mammalian cell membranes:  
Intestinal cell line (Caco-2) 
Ethanol > 5-10%  : long 
incubation time of 60 min 
Loss of viability, leakage of contents and 
disruption of tight junctions 
Meiller TF et al (2005) 
(63)  
In vivo human study  21.6% ethanol, 30 second rinse Recoverable virions of herpes simplex types I 
and II to 0 post rinse; at 30 minutes all lower 
than pre-rinse, 11/20 remained 0   
Meiller TF et al (2005) 
(63) 
In vivo human repeat study  21.6% ethanol, 30 second rinse 0 recoverable virions in 18/20 post rinse and 
12/20 at 30 min; at 60 min all < than baseline 
Sattar et al, (unpublished 
data). 
iFngerpads of adults; Dried inocula; human 
respiratory coronavirus 229E 
Hand gels with 60% and 70% 
ethanol  exposed for 20 seconds 
Viability titre of the virus was reduced by 
>99.99% in both cases 
 
Table 1 – In vitro and in vivo data supporting the effects of ethanol on biomembranes or enveloped viruses.  Studies cited in our text are 
summarized above for type, ethanol amount and outcome.  They are listed in order of model membranes, followed by in vitro studies on viruses, 
studies on mammalian cell membranes, then in vivo studies.  Ethanol concentrations were listed also, in some cases, whether v/v, or w/v was used 
was not provided in the study.  In all studies, refer to the primary literature for full information on the impact of ethanol on the membrane.  
Phosphatidylcholine: PC, phosphatidylethanolamine: PE.  
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Spike protein
Viral envelope
mol% of ER membrane lipids:
Phophatidylcholine 58%
Phosphatidylethanolamine 22%,
Phosphatidylserine 3%
Phosphatidylinositol 10%
Sphingomyelin 3%
Cholesterol 0.018%
Reviewed in: VanMeer, Trends Cell Biol. 1998;8(1):29-33
Figure 1. Cartoon representation of the SARS-CoV-2 glycoprotein, embedded in the viral
envelope, along with membrane disrupting agents. Ribbon diagramwas obtained fromWrapp
et al (ref58), chemical structures were from PubChem (https://pubchem.ncbi.nlm.nih.gov/) and
Nieto-Garai et al (ref 60)
Phospholipids/sphingomyelin
Cholesterol
Ethanol causing 
interdigitation of 
phospholipids
Ethanol
Chlorhexidine
Hydrogen 
peroxide
Cetylpyridinium chloride
Povidone-iodine
Membrane 
disrupting agents
Fatty acid
Lipidomimetics: J391B and IBS70
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